What modality (urine catecholamines, PET, MIBG) is the most sensitive for evaluation of treatment response in a patient with high-risk neuroblastoma?  

Assessment of treatment response for patients with neuroblastoma has been formally defined with the International Neuroblastoma Response Criteria (INRC), most recently updated by Park et al., in 2017 (PMID 28471719). Overall response integrates tumor response in the primary tumor (by CT or MRI), sof...